StreetAlpha.app
Home › Stocks › VRTX

Vertex Pharmaceuticals Inc / MA (VRTX)

Healthcare
$515.02
▼ −1.08%
LAST CLOSE · NOV 20

Vertex Pharmaceuticals develops and sells prescription medicines for cystic fibrosis, blood disorders, acute pain and serious kidney diseases. It last closed at $515.02 on Nov 20, down 1.08% on the day. The next earnings report for VRTX is expected around Thu, Feb 11, 2027, after the close. For the quarter ended Sep 2026, VRTX reported EPS of $2.56 on revenue of $3.44B, with revenue up 11.8% from a year ago. Over its last 8 reports the stock moved an average of 5.9% the session after earnings. Over the last 12 months VRTX insiders bought $0 of stock on the open market and sold $140.1M, according to SEC Form 4 filings.

AI Auto Pilots
Is VRTX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold VRTX.

Key Stats

Last 12 months
Results
Revenue
$13.0B
+10.5% vs a year ago
Net income
$4.0B
+8.2% vs a year ago
EPS (diluted)
$15.54
+9.4% vs a year ago
Free cash flow
$3.2B
24.7% margin
Valuation
Market cap
$131B
253.5M shares
P/E
33.1
Price over 12 month EPS
Price to sales
10.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$5.0B
At Sep 30
Debt
$4.5B
At Sep 30
Shareholder equity
$20.9B
Buybacks
$1.1B
Last 12 months
CEOReshma Kewalramani
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $7.6B$7.6BFY2021FY2022: $8.9B$8.9BFY2022FY2023: $9.9B$9.9BFY2023FY2024: $11.0B$11.0BFY2024FY2025: $12.0B$12.0BFY2025

From VRTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
Feb 11
Estimated date · After the close
Reported EPS
$2.56
Quarter ended Sep 2026
Year ago EPS
$4.20
−39.0% on a GAAP basis
Revenue
$3.44B
+11.8% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $3.53Dec '24Mar 2025: $2.49Mar '25Jun 2025: $3.99Jun '25Sep 2025: $4.20Sep '25Dec 2025: $4.64Dec '25Mar 2026: $4.02Mar '26Jun 2026: $4.31Jun '26Sep 2026: $2.56Sep '26Latest $2.56
Revenue by quarter
Dec 2024: $2.91BDec '24Mar 2025: $2.77BMar '25Jun 2025: $2.96BJun '25Sep 2025: $3.08BSep '25Dec 2025: $3.19BDec '25Mar 2026: $2.99BMar '26Jun 2026: $3.33BJun '26Sep 2026: $3.44BSep '26Latest $3.44B
How VRTX moved after its last 8 reports
Average move the session after a report ±5.9%
Nov 2, 2026After the close−4.0%
Aug 3, 2026After the close+1.7%
May 4, 2026After the close−1.3%
Feb 12, 2026After the close+5.7%
Nov 3, 2025After the close−1.0%
Aug 4, 2025After the close−20.6%
May 5, 2025After the close−10.0%
Feb 10, 2025After the close−3.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on VRTXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on VRTX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on VRTX

Technical Analysis

VRTX · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend

The stock is 4% below its 20 day and 2% below its 50 day average. It is 6% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 41). The nearest support is the swing low (Oct 27) at $509.20, and the nearest resistance the 100 day average at $516.69.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 3.0%/day
Key levels
$568.6752 week high+10.4%
$538.0420 day average+4.5%
$526.33Pivot R1+2.2%
$522.7350 day average+1.5%
$520.06Pivot+1.0%
$517.68Swing high (Oct 15)+0.5%
$516.69100 day average+0.3%
$515.02Last close
$509.20Swing low (Oct 27)−1.1%
$508.76Pivot S1−1.2%
$484.88200 day average−5.9%
$412.2752 week low−20.0%
Indicators
RSI (14)40.85Middle of its rangeNeutral
MACD1.30Below its signal lineBearish
Stochastic10.0Near the bottom of its rangeOversold
ADX (14)11.6No clear trend
Williams %R-97.5Oversold below −80, overbought above −20Oversold
CCI (20)-134.9Oversold below −100, overbought above 100Oversold
Rate of change−5.9%Change over 10 sessionsBearish
ATR (14)$15.34Typical daily range, 3.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for VRTX

What happened before

See how VRTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow VRTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How VRTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for VRTXHow many large options trades hit VRTX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

VRTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲922 buying vs 685 selling
  • ▼Held by funds -1.1 pts
  • ▲Funds holding +33
  • ▲Superinvestors: 4 added, 1 cut
  • ▼Put/call 1.42 to 2.32
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1,7981,765+1.9%
In funds' top 101912+58.3%
Held by funds94.5%95.6%−1.1 pts
New / increased151 / 771175 / 703+5.0%
Reduced / sold out576 / 109617 / 111−5.9%
Put/call ratio2.321.42+63.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See VRTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

VRTX Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$140.1M54 sales · 14 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $37.2M2026-01 sold $6.5M2026-02 sold $64.4M2026-03 sold $5.1M2026-04 sold $439K2026-05 sold $5.3M2026-06 sold $3.7M2026-07 sold $2.0M2026-11 sold $15.4MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 16Sangeeta N. BhatiaDirectorSale plan271$547.86$148K
Nov 16Nancy ThornberryDirectorSale plan1,000$547.86$548K
Nov 12Charles F Wagner JrEvp, Co & FoSale plan15,286$547.87$8.4M
Nov 6Reshma KewalramaniCEO & PresidentSale plan11,866$531.53$6.3M
Jul 2Duncan McKechnieEVP, Chief Commercial OfficerSale plan1,541$519.00$800K
Jul 2Ourania TatsisEVP, Chief Reg. & Quality Off.Sale plan1,500$524.99$787K
Every insider buy and sale for VRTX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See VRTX insider trades →

From SEC Form 4 filings by VRTX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

VRTX Stock Buybacks

See all S&P 500 buybacks →
Spent, 12 months
$1.1B
0.8% yield
Left in program
$2.5B
1.9% of value
Shares outstanding, 12 months
−0.1%
Fewer shares
Last quarter
$121.8M
Sep 2026
Avg price paid, last quarter
$486.15
251K shares bought
S&P 500 rank by spending
#178 of 358
 
Spent each quarter, last 3 yearsTop bar $1.1B
Dec 2023: $143.5M, average price $360.62Mar 2024: $140.4M, average price $418.20Jun 2024: $315.8M, average price $429.06Sep 2024: $307.6M, average price $480.60Dec 2024: $427.4M, average price $444.63Mar 2025: $416.9M, average price $447.03Jun 2025: $394.5M, average price $454.12Sep 2025: $1.1B, average price $397.10Dec 2025: $105.1M, average price $409.11Mar 2026: $344.5M, average price $464.79Jun 2026: $455.0M, average price $440.17Sep 2026: $121.8M, average price $486.15
Dec 2023Sep 2026
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.

From the company's 10-Q filed Nov 3, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VRTX is in one of them and how their past VRTX trades turned out.

VRTX in the AI portfolios
Loading…

VRTX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered VRTX in an article yet. Here's the latest on the wider market.

VRTX in the news

VRTX Congress Trades

All congress trades →
Trades, 12 months
6
Buys
3
50%
Sells
3
50%
People
4
Last filed Nov 5
Who traded VRTX · since 2015
Latest 5 filings of 41
Ro KhannaSell (partial)
$1K – $15KTraded Oct 7, 2026Filed Nov 5, 2026
$1K – $15KTraded Sep 4, 2026Filed Oct 7, 2026
$1K – $15KTraded Aug 26, 2026Filed Sep 5, 2026
$1K – $15KTraded Mar 27, 2026Filed Jul 21, 2026
$1K – $15KTraded Jan 29, 2026Filed Feb 2, 2026
PersonTypeAmountTradedFiledDelay
Ro KhannaD · CASell (partial)$1K – $15KOct 7, 2026Nov 5, 202629 d
Ro KhannaD · CABuy$1K – $15KSep 4, 2026Oct 7, 202633 d
David TaylorR · OHSell$1K – $15KAug 26, 2026Sep 5, 202610 d
Alan ArmstrongR · OKBuy$1K – $15KMar 27, 2026Jul 21, 2026116 d
David TaylorR · OHSell$1K – $15KJan 29, 2026Feb 2, 20264 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Vertex Pharmaceuticals Inc / MA

Vertex Pharmaceuticals is a biotechnology company based in Boston, Massachusetts, that develops and sells prescription medicines for serious diseases. Its approved products treat cystic fibrosis, sickle cell disease and beta thalassemia, and acute pain. The company also has clinical programs for kidney diseases, diabetic nerve pain and type 1 diabetes. Its customers include patients, healthcare providers, and insurers and payors that cover its treatments.

Headquarters
Boston, MA
Founded
1989